Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HLS Therapeutics Inc.

www.hlstherapeutics.com

Latest From HLS Therapeutics Inc.

Vascepa Included In European Dyslipidemia Guidelines Ahead Of Approval

Amarin won't seek approval in the EU until later this year, but doctors there are encouraged to consider Vascepa for patients with high triglycerides despite statin therapy. Also, PCSK9 inhibitor guidelines were solidified for very high risk patients.

Cardiovascular Regulation

Amarin Will Double Vascepa Sales Team In Big Bet On Supplemental Approval

Anticipating a label expansion this fall based on the REDUCE-IT cardiovascular outcomes study, Amarin will double its sales force and has raised revenue guidance. Approved to reduce very high triglyceride levels, Vascepa sales total $170m-$174m so far this year.

Life Cycle Management Business Strategies

Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.

Deals Financing

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • HLS Therapeutics Inc.
  • Senior Management
  • Greg Gubitz, CEO
    Tim Hendrickson, CFO
    Gilbert Godin, Pres. & COO
    Sanjiv Sharma, Chief Commercial Officer
    Hemanth Varghese, PhD, Head, Corp. Strategy & Bus. Dev.
  • Contact Info
  • HLS Therapeutics Inc.
    Phone: (647) 495-9000
    10 Carlson Ct., Ste. 701
    Etobicoke, M9W 6L2
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register